Nuvalent, Inc. NUVL
We take great care to ensure that the data presented and summarized in this overview for Nuvalent, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding NUVL
View all-
Deerfield Management Company, L.P. (Series C) New York, NY20MShares$1.74 Billion38.02% of portfolio
-
Paradigm Biocapital Advisors LP New York, NY5MShares$434 Million18.43% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.13MShares$359 Million0.01% of portfolio
-
Black Rock Inc. New York, NY3.02MShares$263 Million0.01% of portfolio
-
Perceptive Advisors LLC New York, NY2.98MShares$259 Million7.96% of portfolio
-
Bain Capital Life Sciences Investors, LLC Boston, MA2.7MShares$234 Million49.52% of portfolio
-
Fairmount Funds Management LLC Philadelphia, PA1.69MShares$147 Million28.04% of portfolio
-
State Street Corp Boston, MA1.24MShares$108 Million0.01% of portfolio
-
Woodline Partners LP San Francisco, CA1.19MShares$104 Million1.11% of portfolio
-
Boxer Capital, LLC San Diego, CA1.12MShares$97.3 Million6.08% of portfolio
Latest Institutional Activity in NUVL
Top Purchases
Top Sells
About NUVL
Nuvalent, Inc., a clinical stage biopharmaceutical company, develops therapies for patients with cancer. Its lead product candidates are NVL-520, a brain-penetrant ROS1-selective inhibitor to inhibit ROS1 fusions that express the normal ROS1 kinase domain without any drug-resistant mutations and remain active in the presence of mutations conferring resistance to approved and investigational ROS1 inhibitors, which is under Phase I development; and NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, central nervous system-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under Phase I/II clinical trial. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.
Insider Transactions at NUVL
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 19
2024
|
James Richard Porter President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
22,000
+9.48%
|
$0
$0.65 P/Share
|
|
Dec 17
2024
|
Alexandra Balcom Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
13,700
+13.54%
|
$41,100
$3.99 P/Share
|
|
Dec 16
2024
|
Henry E. Pelish Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
10,414
+11.22%
|
$0
$0.76 P/Share
|
|
Dec 16
2024
|
James Richard Porter President and CEO |
SELL
Open market or private sale
|
Direct |
27,000
-6.46%
|
$2,322,000
$86.71 P/Share
|
|
Dec 16
2024
|
James Richard Porter President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
27,000
+11.15%
|
$729,000
$27.85 P/Share
|
|
Dec 11
2024
|
Andrew A. F. Hack |
SELL
Open market or private sale
|
Indirect |
1,250,000
-46.34%
|
$110,000,000
$88.0 P/Share
|
|
Dec 05
2024
|
Grant C. Bogle |
BUY
Grant, award, or other acquisition
|
Direct |
3,200
+50.0%
|
-
|
|
Nov 29
2024
|
Alexandra Balcom Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
10,000
-12.04%
|
$950,000
$95.97 P/Share
|
|
Nov 29
2024
|
Alexandra Balcom Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+18.76%
|
$270,000
$27.85 P/Share
|
|
Nov 25
2024
|
Matthew Shair |
SELL
Open market or private sale
|
Indirect |
2,000
-0.3%
|
$192,000
$96.6 P/Share
|
|
Nov 15
2024
|
James Richard Porter President and CEO |
SELL
Open market or private sale
|
Direct |
27,000
-3.28%
|
$2,376,000
$88.47 P/Share
|
|
Nov 15
2024
|
James Richard Porter President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
27,000
+11.15%
|
$729,000
$27.85 P/Share
|
|
Nov 01
2024
|
Darlene Noci Chief Development Officer |
SELL
Open market or private sale
|
Direct |
5,000
-4.53%
|
$440,000
$88.94 P/Share
|
|
Nov 01
2024
|
Darlene Noci Chief Development Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+11.55%
|
$70,000
$14.4 P/Share
|
|
Oct 31
2024
|
Alexandra Balcom Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
10,000
-6.18%
|
$890,000
$89.67 P/Share
|
|
Oct 31
2024
|
Alexandra Balcom Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+18.76%
|
$270,000
$27.85 P/Share
|
|
Oct 28
2024
|
Matthew Shair |
SELL
Open market or private sale
|
Indirect |
2,000
-0.3%
|
$184,000
$92.23 P/Share
|
|
Oct 22
2024
|
James E Flynn Director |
SELL
Open market or private sale
|
Indirect |
2,000,000
-10.34%
|
$194,000,000
$97.75 P/Share
|
|
Oct 15
2024
|
James Richard Porter President and CEO |
SELL
Open market or private sale
|
Direct |
27,000
-6.3%
|
$2,754,000
$102.64 P/Share
|
|
Oct 15
2024
|
James Richard Porter President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
27,000
+11.15%
|
$729,000
$27.85 P/Share
|
Last 12 Months Summary
| Grant, award, or other acquisition | 290K shares |
|---|---|
| Exercise of conversion of derivative security | 339K shares |
| Open market or private sale | 4.9M shares |
|---|